Lilly says Foundayo has captured over 30% of new US patients on oral weight-loss drugs

Eli Lilly said it has captured more than 30% of new U.S. patients receiving oral obesity treatments, narrowing Novo Nordisk's early lead with its Wegovy pill. The update indicates rapid competitive traction for Lilly in the fast-growing oral weight-loss drug market and could support investor expectations for its obesity franchise.